Pernette J. Verschure
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pernette J. Verschure has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Ate D. Kloosterman
Molecular and Cellular Epigenetics, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands
4 shared publicationsHermannus Kempe
Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands
4 shared publications- Marianne G. Rots
Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
4 shared publications - Perry D. Moerland
Department of Epidemiology and Data Science, Amsterdam UMC, Meibergdreef, The Netherlands
4 shared publications Diewertje G. E. Piebes
University of Amsterdam
3 shared publicationsHuub C.J. Hoefsloot
University of Amsterdam, Swammerdam Institute for Life Sciences, Science Park 904, 1098XH Amsterdam, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 38
Functional epigenetic dynamics and transcriptional heterogeneity: Recent advances
- 17 April 2026
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 38
Open AccessFunctional epigenetic dynamics and transcriptional heterogeneity: Recent advances
- Open Access
- 15 July 2025
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 18 (1) , 1-13
Improved epigenetic age prediction models by combining sex chromosome and autosomal markers
Alterations in epigenetic DNA methylation (DNAm) can be used as an accurate and robust method for biological age prediction. We assessed the feasibility of incorporating sex chromosomal DNAm markers into a six autosomal DNAm CpG marker-based age prediction model, since DNAm-based prediction modeling has predominantly relied on analyzing DNAm patterns on autosomes. We employed random forest regression (RFR) to construct age prediction models with publicly available DNAm Infinium 450 K microarray data of sex chromosomes from human whole blood and buffy coat samples and assessed the RFR model performance based on the root-mean squared error (RMSE) and the mean absolute deviation (MAD) of cross-validation. Four types of models were constructed consisting of DNAm probes on sex chromosomes only, on sex chromosomes and autosomes together, on sex chromosomes and/or autosomes with additional stratification by sex and/or age restriction, and reduced models comprising the top best performing sex chromosomal probes combined with six best performing autosomal probes from a previous study. Our data indicated no added predictive value of Y chromosomal DNAm markers in our best-performing prediction model, even though we acknowledged the potential of applying Y chromosomal markers for age prediction. Yet, a significantly improved accuracy of age prediction was observed using a restricted set of X chromosomal combined with the six best predicting autosomal DNAm probes. In this reduced model we noted an RMSE and MAD of 2.54 and 1.89 years, respectively. Particularly, four DNAm markers on the X chromosome exhibited a strong correlation with age, i.e., cg27064949 (DGAT2L6), cg04532200 (PLXNB3), cg01882566 (RPGR) and cg25140188 (annotated to an intergenic region). Our findings illustrate that an age prediction model built with a set of sex chromosomal markers combined with autosomal age-informative markers, may serve as a high accuracy model to predict chronological age and may be even competitive with commonly used model built with autosomal DNAm markers only. This study represents a step forward towards the application of epigenetic autosomal and sex chromosomal combined age prediction models for aging and forensic research. Highlights
- 15 July 2025
- Published by Springer Nature in Epigenetics & Chromatin
- Vol. 18 (1) , 1-13
Open AccessImproved epigenetic age prediction models by combining sex chromosome and autosomal markers
Alterations in epigenetic DNA methylation (DNAm) can be used as an accurate and robust method for biological age prediction. We assessed the feasibility of incorporating sex chromosomal DNAm markers into a six autosomal DNAm CpG marker-based age prediction model, since DNAm-based prediction modeling has predominantly relied on analyzing DNAm patterns on autosomes. We employed random forest regression (RFR) to construct age prediction models with publicly available DNAm Infinium 450 K microarray data of sex chromosomes from human whole blood and buffy coat samples and assessed the RFR model performance based on the root-mean squared error (RMSE) and the mean absolute deviation (MAD) of cross-validation. Four types of models were constructed consisting of DNAm probes on sex chromosomes only, on sex chromosomes and autosomes together, on sex chromosomes and/or autosomes with additional stratification by sex and/or age restriction, and reduced models comprising the top best performing sex chromosomal probes combined with six best performing autosomal probes from a previous study. Our data indicated no added predictive value of Y chromosomal DNAm markers in our best-performing prediction model, even though we acknowledged the potential of applying Y chromosomal markers for age prediction. Yet, a significantly improved accuracy of age prediction was observed using a restricted set of X chromosomal combined with the six best predicting autosomal DNAm probes. In this reduced model we noted an RMSE and MAD of 2.54 and 1.89 years, respectively. Particularly, four DNAm markers on the X chromosome exhibited a strong correlation with age, i.e., cg27064949 (DGAT2L6), cg04532200 (PLXNB3), cg01882566 (RPGR) and cg25140188 (annotated to an intergenic region). Our findings illustrate that an age prediction model built with a set of sex chromosomal markers combined with autosomal age-informative markers, may serve as a high accuracy model to predict chronological age and may be even competitive with commonly used model built with autosomal DNAm markers only. This study represents a step forward towards the application of epigenetic autosomal and sex chromosomal combined age prediction models for aging and forensic research. Highlights
- Open Access
- 24 December 2024
- Published by Springer Nature in Epigenetics Communications
- Vol. 4 (1) , 1-9
Bridging bioengineering and epigenetics: from technical innovations to clinical applications
- 24 December 2024
- Published by Springer Nature in Epigenetics Communications
- Vol. 4 (1) , 1-9
Open AccessBridging bioengineering and epigenetics: from technical innovations to clinical applications
- 17 July 2024
- Published by Springer Nature
- Vol. 2842, 255-265
Plasmid Delivery and Single-Cell Plasmid Expression Analysis for CRISPR/dCas9-Based Epigenetic Editing
To fully exploit the potentials of reprogramming the epigenome through CRISPR/dCas9 systems for epigenetic editing, there is a growing need for improved transfection methods. With the utilization of constructs often with large sizes and the wide array of cell types used to read out the effect of epigenetic editing in different biological applications, it is evident that ongoing optimalization of transfection protocols tailored to each specific experimental setup is essential. Whether the goal is the production of viral particles using human embryonic kidney (HEK) cells or the direct examination of epigenomic modifications in the target cell type, continuous refinement of transfection methods is crucial. In the hereafter outlined protocol, we focus on optimization of transfection protocols by comparing different reagents and methods, creating a streamlined setup for transfection efficiency optimization in cultured mammalian cells. Our protocol provides a comprehensive overview of flow cytometry analysis following transfection not just to improve transfection efficiency but also to assess the expression level of the utilized construct. We showcase our transfection protocol optimization using HEK293T Lenti-X™ and breast cancer MCF-7 cell lines, using a single-guide RNA-containing plasmid. Specifically, we incorporate heat shock treatment for increased transfection efficiency of the MCF-7 cell line. Our detailed optimization protocol for efficient plasmid delivery and measurement of single-cell plasmid expression provides a comprehensive instruction for assessing both transient and sustained effects of epigenetic reprogramming.
- 17 July 2024
- Published by Springer Nature
- Vol. 2842, 255-265
Plasmid Delivery and Single-Cell Plasmid Expression Analysis for CRISPR/dCas9-Based Epigenetic Editing
To fully exploit the potentials of reprogramming the epigenome through CRISPR/dCas9 systems for epigenetic editing, there is a growing need for improved transfection methods. With the utilization of constructs often with large sizes and the wide array of cell types used to read out the effect of epigenetic editing in different biological applications, it is evident that ongoing optimalization of transfection protocols tailored to each specific experimental setup is essential. Whether the goal is the production of viral particles using human embryonic kidney (HEK) cells or the direct examination of epigenomic modifications in the target cell type, continuous refinement of transfection methods is crucial. In the hereafter outlined protocol, we focus on optimization of transfection protocols by comparing different reagents and methods, creating a streamlined setup for transfection efficiency optimization in cultured mammalian cells. Our protocol provides a comprehensive overview of flow cytometry analysis following transfection not just to improve transfection efficiency but also to assess the expression level of the utilized construct. We showcase our transfection protocol optimization using HEK293T Lenti-X™ and breast cancer MCF-7 cell lines, using a single-guide RNA-containing plasmid. Specifically, we incorporate heat shock treatment for increased transfection efficiency of the MCF-7 cell line. Our detailed optimization protocol for efficient plasmid delivery and measurement of single-cell plasmid expression provides a comprehensive instruction for assessing both transient and sustained effects of epigenetic reprogramming.
- 17 July 2024
- Published by Springer Nature
- Vol. 2842, 449-460
Single-Molecule Analysis of Transcription Dynamics to Understand the Relationship Between Epigenetic Alterations and Transcriptional Variability
Heterogeneity in gene expression largely stems from the discontinuous nature of transcription, with transcripts being produced in bursts with defined frequencies. This cell-to-cell variability in transcription within isogenic cell populations is a known phenomenon across numerous genes. Multiple gene regulatory and epigenetic factors have been identified as key contributors to this pulsatile gene activity. Understanding the effects of epigenetic modulation on transcriptional cell-to-cell variability and kinetics of transcriptional activity is crucial for interpreting changes in treatment responsiveness. We present a detailed protocol that guides the assessment of fluctuations in gene expression induced by epigenetic modulation using single-molecule RNA in situ hybridization (smRNA FISH) combined with confocal microscopy imaging, data analysis, and quantification in breast cancer cells. Through smRNA FISH labeling, both mature and nascent transcripts are identified. Subsequently, the number of mature transcripts and the intensity and frequency of nascent transcripts are quantified, and these measurements are used to calculate the burst size and frequency for the labeled gene. By following this step-by-step methodology, insights are obtained into the intricate relationship between epigenetic alterations and the dynamic nature of gene expression in breast cancer cells.
- 17 July 2024
- Published by Springer Nature
- Vol. 2842, 449-460
Single-Molecule Analysis of Transcription Dynamics to Understand the Relationship Between Epigenetic Alterations and Transcriptional Variability
Heterogeneity in gene expression largely stems from the discontinuous nature of transcription, with transcripts being produced in bursts with defined frequencies. This cell-to-cell variability in transcription within isogenic cell populations is a known phenomenon across numerous genes. Multiple gene regulatory and epigenetic factors have been identified as key contributors to this pulsatile gene activity. Understanding the effects of epigenetic modulation on transcriptional cell-to-cell variability and kinetics of transcriptional activity is crucial for interpreting changes in treatment responsiveness. We present a detailed protocol that guides the assessment of fluctuations in gene expression induced by epigenetic modulation using single-molecule RNA in situ hybridization (smRNA FISH) combined with confocal microscopy imaging, data analysis, and quantification in breast cancer cells. Through smRNA FISH labeling, both mature and nascent transcripts are identified. Subsequently, the number of mature transcripts and the intensity and frequency of nascent transcripts are quantified, and these measurements are used to calculate the burst size and frequency for the labeled gene. By following this step-by-step methodology, insights are obtained into the intricate relationship between epigenetic alterations and the dynamic nature of gene expression in breast cancer cells.
- Open Access
- 30 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 102
Functional Validation of the Putative Oncogenic Activity of PLAU
Plasminogen activator, urokinase (PLAU) is involved in cell migration, proliferation and tissue remodeling. PLAU upregulation is associated with an increase in aggressiveness, metastasis, and invasion of several cancer types, including breast cancer. In patients, this translates into decreased sensitivity to hormonal treatment, and poor prognosis. These clinical findings have led to the examination of PLAU as a biomarker for predicting breast cancer prognosis and therapy responses. In this study, we investigated the functional ability of PLAU to act as an oncogene in breast cancers by modulating its expression using CRISPR-deactivated Cas9 (CRISPR-dCas9) tools. Different effector domains (e.g., transcription modulators (VP64, KRAB)) alone or in combination with epigenetic writers (DNMT3A/3L, MSssI) were fused to dCas9 and targeted to the PLAU promoter. In MDA-MB-231 cells characterized by high PLAU expression downregulation of PLAU expression by CRISPR-dCas9-DNMT3A/3L-KRAB, resulted in decreased cell proliferation. Conversely, CRISPR-dCas9-VP64 induced PLAU upregulation in low PLAU expressing MCF-7 cells and significantly increased aggressiveness and invasion. In conclusion, modulation of PLAU expression affected metastatic related properties of breast cancer cells, thus further validating its oncogenic activity in breast cancer cells.
- 30 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 102
Open AccessFunctional Validation of the Putative Oncogenic Activity of PLAU
Plasminogen activator, urokinase (PLAU) is involved in cell migration, proliferation and tissue remodeling. PLAU upregulation is associated with an increase in aggressiveness, metastasis, and invasion of several cancer types, including breast cancer. In patients, this translates into decreased sensitivity to hormonal treatment, and poor prognosis. These clinical findings have led to the examination of PLAU as a biomarker for predicting breast cancer prognosis and therapy responses. In this study, we investigated the functional ability of PLAU to act as an oncogene in breast cancers by modulating its expression using CRISPR-deactivated Cas9 (CRISPR-dCas9) tools. Different effector domains (e.g., transcription modulators (VP64, KRAB)) alone or in combination with epigenetic writers (DNMT3A/3L, MSssI) were fused to dCas9 and targeted to the PLAU promoter. In MDA-MB-231 cells characterized by high PLAU expression downregulation of PLAU expression by CRISPR-dCas9-DNMT3A/3L-KRAB, resulted in decreased cell proliferation. Conversely, CRISPR-dCas9-VP64 induced PLAU upregulation in low PLAU expressing MCF-7 cells and significantly increased aggressiveness and invasion. In conclusion, modulation of PLAU expression affected metastatic related properties of breast cancer cells, thus further validating its oncogenic activity in breast cancer cells.
- Open Access
- 28 December 2021
- Published by Springer Nature in Epigenetics Communications
- Vol. 1 (1) , 1-13
Transcription bursting and epigenetic plasticity: an updated view
The vast majority of eukaryotic transcription occurs in bursts during discrete periods of promoter activity, separated by periods of deep repression and inactivity. Elucidating the factors responsible for triggering transitions between these two states has been extremely challenging, partly due to the difficulties in measuring transcriptional bursting genome-wide, but also due to the vast array of candidate transcriptional and epigenetic factors and their complex and dynamic interactions. Additionally, this long-held view of transcriptional bursting as a two-state process has become increasingly challenged, and a resulting lack in consensus on terminology of the involved events has further complicated our understanding of the molecular mechanisms involved. Here, we review the impact of epigenetics on dynamic gene expression, with a focus on transcription bursting. We summarise current understanding of the epigenetic regulation of transcription bursting and propose new terminology for the interpretation of future results measuring transcription dynamics.
- 28 December 2021
- Published by Springer Nature in Epigenetics Communications
- Vol. 1 (1) , 1-13
Open AccessTranscription bursting and epigenetic plasticity: an updated view
The vast majority of eukaryotic transcription occurs in bursts during discrete periods of promoter activity, separated by periods of deep repression and inactivity. Elucidating the factors responsible for triggering transitions between these two states has been extremely challenging, partly due to the difficulties in measuring transcriptional bursting genome-wide, but also due to the vast array of candidate transcriptional and epigenetic factors and their complex and dynamic interactions. Additionally, this long-held view of transcriptional bursting as a two-state process has become increasingly challenged, and a resulting lack in consensus on terminology of the involved events has further complicated our understanding of the molecular mechanisms involved. Here, we review the impact of epigenetics on dynamic gene expression, with a focus on transcription bursting. We summarise current understanding of the epigenetic regulation of transcription bursting and propose new terminology for the interpretation of future results measuring transcription dynamics.
- Open Access
4sUDRB-sequencing for genome-wide transcription bursting quantification in breast cancer cells
Epigenetics maintains cell-identity specific gene-expression patterns. However, within a population of isogenic cells of the same identity, a substantial variability in gene expression and responsiveness is still observed. Transcription bursting is a substantial source of this gene-expression variability or ‘noise’, contributing to phenotypic heterogeneity and potentially driving both physiological and pathological processes such as differentiation or tumorigenesis and drug resistance. Identification of transcription-bursting dynamics at a genome-wide scale has been restricted to inferring bursts in mRNA production computationally from the heterogeneity of mRNA levels in single cell transcriptomic data. Systematic characterisation of the genomic and epigenetic chromatin context of genes with defined transcription bursting behaviour has been incomplete. Here, we measured the bursting of transcription itself by genome-wide nascent RNA sequencing of breast cancer MCF-7 cells upon synchronisation of transcription with a transcription elongation inhibitor and by calibration using live cell imaging of nascent PP7-tagged GREB1 transcription. Comparing across the entire genome, we find transcription bursting to be ubiquitous, with burst sizes of up to 160 transcripts. Transcription bursting is strongly correlated with steady state gene expression between genes, whereas both burst frequency and nascent transcript degradation only correlate weakly. Individual genes deviate strongly from this trend and engage both in anomalous burst size and frequency. We find that the presence of the TATA box or Inr sequence within gene promoters are significantly associated with a larger burst size, as are promoter-associated YY1 and E2F1 transcription-factor binding motifs. Enrichment of the transcription start site with epigenetic marks such as H3K79me2 and H3K27ac is also strongly associated with the transcription burst size. Finally, we show that in these MCF-7 breast-cancer cells, genes with a larger transcription burst size exhibit a larger immediate transcriptional response following endocrine drug treatment. Our genome-wide transcription-bursting analysis method paves the way to elucidate the dynamic role of epigenetic regulation on dynamic transcription in pathophysiology.
Open Access4sUDRB-sequencing for genome-wide transcription bursting quantification in breast cancer cells
Epigenetics maintains cell-identity specific gene-expression patterns. However, within a population of isogenic cells of the same identity, a substantial variability in gene expression and responsiveness is still observed. Transcription bursting is a substantial source of this gene-expression variability or ‘noise’, contributing to phenotypic heterogeneity and potentially driving both physiological and pathological processes such as differentiation or tumorigenesis and drug resistance. Identification of transcription-bursting dynamics at a genome-wide scale has been restricted to inferring bursts in mRNA production computationally from the heterogeneity of mRNA levels in single cell transcriptomic data. Systematic characterisation of the genomic and epigenetic chromatin context of genes with defined transcription bursting behaviour has been incomplete. Here, we measured the bursting of transcription itself by genome-wide nascent RNA sequencing of breast cancer MCF-7 cells upon synchronisation of transcription with a transcription elongation inhibitor and by calibration using live cell imaging of nascent PP7-tagged GREB1 transcription. Comparing across the entire genome, we find transcription bursting to be ubiquitous, with burst sizes of up to 160 transcripts. Transcription bursting is strongly correlated with steady state gene expression between genes, whereas both burst frequency and nascent transcript degradation only correlate weakly. Individual genes deviate strongly from this trend and engage both in anomalous burst size and frequency. We find that the presence of the TATA box or Inr sequence within gene promoters are significantly associated with a larger burst size, as are promoter-associated YY1 and E2F1 transcription-factor binding motifs. Enrichment of the transcription start site with epigenetic marks such as H3K79me2 and H3K27ac is also strongly associated with the transcription burst size. Finally, we show that in these MCF-7 breast-cancer cells, genes with a larger transcription burst size exhibit a larger immediate transcriptional response following endocrine drug treatment. Our genome-wide transcription-bursting analysis method paves the way to elucidate the dynamic role of epigenetic regulation on dynamic transcription in pathophysiology.
- Open Access
Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer
Breast cancer is one of the leading causes of death for women worldwide. Patients whose tumors express Estrogen Receptor α account for around 70% of cases and are mostly treated with targeted endocrine therapy. However, depending on the degree of severity of the disease at diagnosis, 10 to 40% of these tumors eventually relapse due to resistance development. Even though recent novel approaches as the combination with CDK4/6 inhibitors increased the overall survival of relapsing patients, this remains relatively short and there is a urgent need to find alternative targetable pathways. In this study we profiled the early phases of the resistance development process to uncover drivers of this phenomenon. Time-resolved analysis revealed that ATF3, a member of the ATF/CREB family of transcription factors, acts as a novel regulator of the response to therapy via rewiring of central signaling processes towards the adaptation to endocrine treatment. ATF3 was found to be essential in controlling crucial processes such as proliferation, cell cycle, and apoptosis during the early response to treatment through the regulation of MAPK/AKT signaling pathways. Its essential role was confirmed in vivo in a mouse model, and elevated expression of ATF3 was verified in patient datasets, adding clinical relevance to our findings. This study proposes ATF3 as a novel mediator of endocrine resistance development in breast cancer and elucidates its role in the regulation of downstream pathways activities.
Open AccessTime-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer
Breast cancer is one of the leading causes of death for women worldwide. Patients whose tumors express Estrogen Receptor α account for around 70% of cases and are mostly treated with targeted endocrine therapy. However, depending on the degree of severity of the disease at diagnosis, 10 to 40% of these tumors eventually relapse due to resistance development. Even though recent novel approaches as the combination with CDK4/6 inhibitors increased the overall survival of relapsing patients, this remains relatively short and there is a urgent need to find alternative targetable pathways. In this study we profiled the early phases of the resistance development process to uncover drivers of this phenomenon. Time-resolved analysis revealed that ATF3, a member of the ATF/CREB family of transcription factors, acts as a novel regulator of the response to therapy via rewiring of central signaling processes towards the adaptation to endocrine treatment. ATF3 was found to be essential in controlling crucial processes such as proliferation, cell cycle, and apoptosis during the early response to treatment through the regulation of MAPK/AKT signaling pathways. Its essential role was confirmed in vivo in a mouse model, and elevated expression of ATF3 was verified in patient datasets, adding clinical relevance to our findings. This study proposes ATF3 as a novel mediator of endocrine resistance development in breast cancer and elucidates its role in the regulation of downstream pathways activities.
- Open Access
- 21 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3634
KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and Is Resilient to TGFβ1 Activation
Epigenetic editing, an emerging technique used for the modulation of gene expression in mammalian cells, is a promising strategy to correct disease-related gene expression. Although epigenetic reprogramming results in sustained transcriptional modulation in several in vivo models, further studies are needed to develop this approach into a straightforward technology for effective and specific interventions. Important goals of current research efforts are understanding the context-dependency of successful epigenetic editing and finding the most effective epigenetic effector(s) for specific tasks. Here we tested whether the fibrosis- and cancer-associated PLOD2 gene can be repressed by the DNA methyltransferase M.SssI, or by the non-catalytic Krüppel associated box (KRAB) repressor directed to the PLOD2 promoter via zinc finger- or CRISPR-dCas9-mediated targeting. M.SssI fusions induced de novo DNA methylation, changed histone modifications in a context-dependent manner, and led to 50%–70% reduction in PLOD2 expression in fibrotic fibroblasts and in MDA-MB-231 cancer cells. Targeting KRAB to PLOD2 resulted in the deposition of repressive histone modifications without DNA methylation and in almost complete PLOD2 silencing. Interestingly, both long-term TGFβ1-induced, as well as unstimulated PLOD2 expression, was completely repressed by KRAB, while M.SssI only prevented the TGFβ1-induced PLOD2 expression. Targeting transiently expressed dCas9-KRAB resulted in sustained PLOD2 repression in HEK293T and MCF-7 cells. Together, these findings point to KRAB outperforming DNA methylation as a small potent targeting epigenetic effector for silencing TGFβ1-induced and uninduced PLOD2 expression.
- 21 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3634
Open AccessKRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and Is Resilient to TGFβ1 Activation
Epigenetic editing, an emerging technique used for the modulation of gene expression in mammalian cells, is a promising strategy to correct disease-related gene expression. Although epigenetic reprogramming results in sustained transcriptional modulation in several in vivo models, further studies are needed to develop this approach into a straightforward technology for effective and specific interventions. Important goals of current research efforts are understanding the context-dependency of successful epigenetic editing and finding the most effective epigenetic effector(s) for specific tasks. Here we tested whether the fibrosis- and cancer-associated PLOD2 gene can be repressed by the DNA methyltransferase M.SssI, or by the non-catalytic Krüppel associated box (KRAB) repressor directed to the PLOD2 promoter via zinc finger- or CRISPR-dCas9-mediated targeting. M.SssI fusions induced de novo DNA methylation, changed histone modifications in a context-dependent manner, and led to 50%–70% reduction in PLOD2 expression in fibrotic fibroblasts and in MDA-MB-231 cancer cells. Targeting KRAB to PLOD2 resulted in the deposition of repressive histone modifications without DNA methylation and in almost complete PLOD2 silencing. Interestingly, both long-term TGFβ1-induced, as well as unstimulated PLOD2 expression, was completely repressed by KRAB, while M.SssI only prevented the TGFβ1-induced PLOD2 expression. Targeting transiently expressed dCas9-KRAB resulted in sustained PLOD2 repression in HEK293T and MCF-7 cells. Together, these findings point to KRAB outperforming DNA methylation as a small potent targeting epigenetic effector for silencing TGFβ1-induced and uninduced PLOD2 expression.